Lightbridge (LTBR) Q2 2024 earnings summary

Executive summary

• Achieved a key milestone with successful extrusion of Lightbridge Fuel rod sample at Idaho National Laboratory, advancing fuel development efforts across multiple sites and targeting both existing and next-generation reactors.

• Expanded R&D team and collaborations with U.S. and international partners, including MIT, Texas A&M, RATEN ICN in Romania, and Centrus Energy, with ongoing feasibility and engineering studies.

• Passage of the ADVANCE Act is expected to streamline regulatory licensing for advanced nuclear technologies, supporting industry growth and Lightbridge Fuel's market entry.

• Demand for clean, reliable energy is rising due to AI-driven data centers, crypto mining, and electrification, positioning advanced nuclear as a key solution.

• Lightbridge projects significant R&D investment over the next 12–15 months and anticipates demonstration of lead test rods/assemblies in commercial reactors in the 2030s, with initial purchase orders expected 15–20 years from now.

Financial highlights

• Working capital was $26.4 million at June 30, 2024, down from $28.3 million at December 31, 2023.

• Cash and cash equivalents were $27.1 million at June 30, 2024, a decrease from $28.6 million at December 31, 2023.

• Net loss for Q2 2024 was $2.4 million, compared to $1.7 million in Q2 2023; net loss for the six months ended June 30, 2024 was $5.2 million, up from $3.7 million year-over-year.

• R&D expenses rose to $0.9 million in Q2 2024 from $0.4 million in Q2 2023, mainly due to increased project labor and compensation.

• Cash used in operating activities for the first half of 2024 was $3.7 million, up from $3.0 million in the first half of 2023.

Outlook and guidance

• Projected R&D investment of approximately $8.3 million over the next 12–15 months.

• Upcoming milestones include irradiation testing of enriched uranium fuel samples, completion of CANDU reactor feasibility study, and front-end engineering for a pilot fabrication facility.

• Cash balance is expected to cover operating needs for the next 12 months, but long-term R&D will require additional funding from government, strategic partners, or further equity offerings.

• R&D expenses are expected to increase as new agreements are finalized and project scope expands.

• Plans to seek additional government funding and strategic alliances for future R&D and commercialization.